Today: 19 May 2026
Browse Category

NYSE:CI 4 October 2025 - 30 October 2025

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna shares closed at $299.12 on Oct 29, down 3% for the week, before rising to $303 in Oct 30 premarket trading. The company reported Q3 revenue of $69.7 billion and net income of $1.87 billion, beating forecasts and reaffirming its full-year outlook. Cigna launched a new pharmacy benefit model and Evernorth invested $3.5 billion in Shields Health. Analyst consensus remains bullish with a $370–$377 price target.
30 October 2025
···
Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

The S&P 500 and Dow closed at record highs Friday, with the Dow up 0.5% despite a third day of the U.S. government shutdown. The September jobs report was delayed, but traders expect a Fed rate cut in late October. Utilities and health insurers led gains, while tech stocks lagged. Palantir dropped 7.5% after a U.S. Army memo flagged security issues; Applied Materials fell 3% on China export curbs.
4 October 2025
····
1 2

Stock Market Today

  • Topps Tiles Shares Stable as Turnaround Strategy Shows Progress Amid Market Challenges
    May 19, 2026, 6:02 AM EDT. Topps Tiles (LSE: TPT), a 34p penny stock, reported mixed but positive interim results for 2026, showing stability after a 55% five-year decline. The Mission 365 plan aims to grow sales to £365 million with profitable margins. Adjusted revenue was slightly down 0.2% pro forma, but operating profit rose 17.3%. The company outperformed the UK home improvement market despite inflation and weak consumer sentiment. Management expects revenue to improve in the second half and forecasts modest profit growth if economic conditions hold. Net debt increased to £3.1 million but is supported by a £30 million banking facility. Investors await further clarity on the full-year dividend policy.

Latest articles

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

19 May 2026
Virax Biolabs shares surged 53.1% Monday to $0.2350 and climbed another 17.1% in early Tuesday premarket trading, hitting $0.2751. The rally followed a paid RedChip TV appearance and a May 15 ownership filing showing Armistice Capital with a 4.99% stake. No new clinical or product updates were posted. Trading volume Monday reached about 765.2 million shares.
Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

19 May 2026
Amesite Inc. shares surged 218% to $2.50 in premarket trading after announcing its largest NurseMagic deployment with a 2,700-patient home-care client. The company disclosed $83,332 in quarterly revenue and a $678,061 net loss, with cash at $740,711 before a $2.2 million April financing. Amesite did not reveal the new contract’s value or customer name. Its latest filing cited “substantial doubt” about ongoing operations.
Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

19 May 2026
Alphabet shares rose in pre-market trading Tuesday after Google and Blackstone announced a U.S. AI cloud venture, with Blackstone committing $5 billion to add 500 megawatts of data-center capacity by 2027. Alphabet’s Class A shares closed Monday at $396.94 and were quoted at $401.09 before the market opened. The move coincides with the first day of Google I/O and follows strong Q1 earnings.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop